At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Johannes Lübke, University Hospital Mannheim, Mannheim, DE, delivered a presentation on diagnosis, risk stratification, and response assessment in advanced systemic mastocytosis (AdvSM).
Lübke discusses the current diagnostic framework for systemic mastocytosis, emphasizing the need for integrated disease assessment beyond established diagnostic criteria. He explores the role of molecular profiling in prognostic risk stratification, evolving prognostic models in the era of KIT-targeted therapy, current and emerging approaches to response assessment, and the complementary role of patient-reported outcomes in evaluating disease burden and treatment benefit.
This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.
","author_name":"Scientific Education Support"}